The exosome therapy market in healthcare and pharmaceutical industry is expected to reach USD 32 million in 2022 and anticipated to grow at a CAGR of 41.2% during the forecast period 2023-2040.

In recent years, extracellular vesicle-based therapies have gained significant traction in the medical field, attracting considerable attention from industry stakeholders due to their promising applications across various medical conditions. This heightened interest primarily arises from their precise targeting capabilities, facilitation of tissue regeneration, and their potential to alleviate inflammation and chronic pain. Exosomes, a specific type of membrane-bound extracellular vesicles, have particularly garnered attention due to their manifold advantages, leading to extensive research across disease diagnosis, drug delivery, and therapeutic interventions. This growing body of research has prompted both industry and non-industry entities to delve into developing exosome-based therapeutics, with some progressing through clinical trials. Moreover, the COVID-19 pandemic has notably accelerated the exploration of exosome therapy, evident in the increased submissions of investigational new drug (IND) applications targeting COVID-19 complexities and associated complications.

A recent comprehensive review encompassing over 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use revealed that these exosomes demonstrated favorable outcomes in more than 70% of the conducted studies. This substantiates the efficacy and potential of MSC-derived exosomes across diverse therapeutic modalities, further highlighting their importance in advancing medical interventions.

Report Coverage
? The analysis focuses on the exosome therapy market, considering the types of therapy, target indications, therapeutic areas, route of administration, and geographical distribution.
? Examination of factors, including drivers, restraints, opportunities, and challenges, impacting market growth is conducted within the report.
? Evaluation of potential advantages and barriers within the market landscape is provided, along with insights into the competitive environment among key market players.
? Revenue forecasts for market segments are projected across four major regions.
? Detailed explanation of exosomes, encompassing various extracellular vesicle types, their origin, secretion, membrane composition, developmental process, and therapeutic applications. Included are discussions on advantages, risks associated with exosome therapy, and future prospects.
? Assessment based on development phases, technology platforms, payload types, target disease indications, therapeutic areas, biological targets, administration routes, therapy types, companies involved, establishment year, size, and headquarters.
? Comprehensive profiles of major exosome therapy companies, focusing on their pipeline, financial data, product portfolio, recent developments, and future outlook.
? Detailed information on leading exosome therapies in advanced development phases, covering product portfolio, clinical trial details, phase, locations, patient enrollment, and trial duration.
? Examination of completed and ongoing clinical trials related to exosome therapeutics, based on trial status, registration year, sponsors, study designs, patient enrollment, trends, participant demographics, and trial locations.
? In-depth analysis of grants awarded to research institutes for exosome therapeutic projects from 2017-2022, focusing on funding details, grant purposes, recipient organizations, and emerging focus areas.
? Analysis of events attended by exosome therapy developers, encompassing event details, locations, participant demographics, active organizers, industry involvement, participant designations, and speakers.
? Examination of partnerships established since 2017, covering research agreements, licensing, manufacturing, development/commercialization deals, mergers/acquisitions in the exosome therapy industry.
? Analysis of investments made in exosome therapeutic companies since 2017, including grants, financing types, IPOs, offerings, debt financing, equity, and funding details.
? Evaluation of start-ups engaged in exosome therapeutics based on pipeline strength, maturity, financial backing, investor count, partnerships, and start-up health indexing.
? A case study on companies offering exosome development and manufacturing services, covering service types, isolation, characterization, purification methods, manufacturing processes, scalability, and scale of operation.
? Examination of exosome therapeutics that did not progress to later clinical stages, based on discontinuation status, target diseases, administration routes, and sponsorship type.


Key Market Companies
? Coya Therapeutics
? Evox Therapeutics
? Curexsys
? EV Therapeutics
? SHIFTBIO